Group 1: Macroeconomic Insights - Goldman Sachs Chief Economist Jan Hatzius indicated that the recent US-China Geneva negotiations exceeded expectations, but uncertainties regarding US tariff policies remain significant, negatively impacting US economic growth [1] - Hatzius emphasized that trade between nations is not a zero-sum game, which is crucial for economic decision-makers to understand [1] - The firm noted that after the US-China trade negotiations, risks are gradually being released, and there is potential for valuation recovery in the e-commerce sector [2] Group 2: Industry-Specific Analysis - Goldman Sachs Asian Internet Research Head Ronald Keung pointed out that the potential adjustment of small package tax exemption policies by multiple countries could impact the e-commerce industry [2] - Goldman Sachs Asian Pharmaceutical Research Head Ziyi Chen analyzed that the US tariff measures on pharmaceuticals are filled with uncertainties, but the impact on China's pharmaceutical industry is limited, although supply chain costs may increase [2] - Goldman Sachs Industrial Technology Analyst Jacqueline Du discussed the development stage and competitive advantages of humanoid robots in China, noting that the industry is currently in the commercialization phase [3] Group 3: Automotive Sector Insights - Goldman Sachs Automotive Analyst Tina Hou observed that the competition in China's new energy vehicle market has entered a deep-water phase, with price wars still ongoing despite a slight narrowing in price reductions compared to last year [3] - The peak of capacity expansion in the new energy vehicle market has passed, but the "elimination race" among over 50 competing car manufacturers is still ongoing [3] Group 4: Investment Strategy - Goldman Sachs Chief China Equity Strategist Kinger Lau highlighted that despite ongoing external pressures, the resilience of Chinese assets is becoming increasingly evident, driven by domestic demand and policy support [3] - The firm noted that the structural opportunities for consumption upgrades and industrial transformation are being propelled by dual forces of domestic demand and policy incentives [3]

Group 1 - The Hong Kong pharmaceutical outsourcing sector is experiencing a strong performance, with the Hang Seng Medical Index ETF (159557) rising by 1.11% and a turnover rate exceeding 5%, indicating active trading [1] - Notable stocks within the ETF include WuXi AppTec and WuXi Biologics, both increasing by nearly 9%, along with other companies like MicroPort Medical and WuXi PharmaTech also showing gains [1] - The upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting, scheduled from May 30 to June 3 in Chicago, is expected to showcase significant advancements in cancer treatment and clinical practice innovations [1] Group 2 - AI is demonstrating significant value across various medical scenarios, including medical imaging analysis, precision medicine, drug development, and gene sequencing [2] - The pharmaceutical sector in the A-share market is currently at historical lows in terms of stock prices, valuations, and fund holdings, indicating potential for improvement as the fundamentals are nearing a clearing phase [2] - Recent favorable policies in the pharmaceutical sector are expected to lead to a gradual recovery, particularly in the hospital market, which has been impacted by previous anti-corruption measures and centralized procurement [2]

Core Insights - The A-share market experienced slight adjustments with the Shanghai Composite Index closing down 0.02% at 3,339.93 points, while the Shenzhen Component and ChiNext Index fell by 0.26% and 0.31% respectively. The total trading volume in the A-share market reached 1.03 trillion RMB, with over 3,400 stocks declining [2][7] - In the industry sector, textiles and apparel, as well as the environmental protection industry, led the gains, while basic chemicals and agriculture, forestry, animal husbandry, and fishery sectors saw declines. Concept sectors such as medical waste treatment and combustible ice performed well, whereas epoxy propane and genetically modified concepts faced significant losses [2][7] - The Hong Kong market also saw declines, with the Hang Seng Index down 0.53% and the Hang Seng Tech Index down 0.15%. Internationally, all three major U.S. indices closed lower, with the Dow Jones down 0.58%, S&P 500 down 0.56%, and Nasdaq down 0.51% [2][7] Important News - A seminar on the semiconductor industry was held in Beijing, attended by representatives from over 40 semiconductor companies from China and Europe. The meeting focused on enhancing economic and trade cooperation in the semiconductor sector, emphasizing the importance of mutual advantages and compliance with laws to maintain global semiconductor supply chain security [3][8] Market Analysis - As of May 26, the Shanghai Composite Index rose by 2.07% compared to the end of April, indicating a mixed performance among major A-share indices. The liquidity in the A-share market remained stable, with a slight decrease in the number of newly established equity funds and minor reductions in shareholdings by major stakeholders. However, trading volume rebounded, and the scale of locked-up shares released decreased [9] - Investor confidence has improved, with significant inflows into popular sectors such as automotive and biopharmaceuticals, driven by easing U.S.-China tariff policies and supportive financial measures. The market's overall trading activity has seen fluctuations, but sectors like specialized and innovative driving concepts continue to attract attention [9][10] Industry Outlook and Recommendations - The easing of U.S.-China trade tensions has positively impacted market sentiment, with both countries' major indices showing signs of stabilization. The domestic economy has shown resilience, with April data indicating stable growth amid macroeconomic policy support. The focus on expanding domestic demand is expected to enhance consumer spending and drive growth in the consumer sector [10][12] - The China Securities Regulatory Commission (CSRC) is set to introduce a series of financial policies aimed at stabilizing the market and enhancing liquidity. These measures include reforms in the STAR Market and ChiNext, aimed at improving institutional inclusivity and adaptability. The report suggests focusing on sectors that will benefit from domestic consumption growth and technological advancements [12]

Core Viewpoint - *ST Jiyuan's stock has been decided to be delisted by the Shenzhen Stock Exchange due to its closing price being below 1 yuan for twenty consecutive trading days, effective May 29, 2025 [2] Group 1: Company Overview - *ST Jiyuan primarily operates in the pharmaceutical and health industry, encompassing pharmaceutical manufacturing, retail, research and development, medical care, and investment [2] - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in August 2010 [2] Group 2: Delisting Details - The decision for delisting was made on May 26, 2025, and the company is required to ensure its shares can enter the National Small and Medium Enterprises Share Transfer System within 45 trading days after delisting [2] - The company will not enter a delisting transition period [2] Group 3: Future Actions - *ST Jiyuan has appointed Shanxi Securities Co., Ltd. as its main broker to assist with share transfer services and related matters following the delisting [3] - An agreement for share transfer services was signed on May 27, 2025, to handle the necessary procedures for the delisting [3]

Core Viewpoint - *ST Jiyao (300108) has been decided to be delisted by the Shenzhen Stock Exchange due to triggering mandatory delisting conditions, with the delisting date set for May 29, 2025 [1][2]. Summary by Sections Company Announcement - On May 28, 2025, *ST Jiyao announced that its stock would be terminated from listing by the Shenzhen Stock Exchange, effective May 29, 2025, without entering a delisting adjustment period [1]. - The company received the termination notice on May 26, 2025, and is required to ensure its shares can enter the National Equities Exchange and Quotations (NEEQ) within 45 trading days after delisting [1]. Shareholder Information - As of March 31, 2025, *ST Jiyao had 28,056 shareholders [2]. Stock Trading Activity - Prior to its suspension on April 24, 2025, *ST Jiyao's stock price was reported at 0.21 CNY per share. On the last trading day before suspension, the stock opened at a limit-down price of 0.19 CNY, briefly rising to 0.23 CNY with a turnover rate of 29.42%, and a total trading volume of nearly 40 million CNY [4]. - The stock experienced significant price fluctuations, with a cumulative price drop deviation of 30% over two consecutive trading days and 50% over four trading days, indicating severe abnormal trading conditions [4]. Company Background - *ST Jiyao, established in 2000, operates in the pharmaceutical industry, including manufacturing, wholesale, retail, and healthcare services. The company transitioned from a chemical focus to pharmaceuticals through acquisitions starting in 2014 [6]. - The company has faced continuous losses since 2019, with a reported revenue of 333.33 million CNY in 2024, a decrease of 3.69% year-on-year, and a net loss of 439.43 million CNY, worsening from a loss of 349.31 million CNY in the previous year [6][7]. Financial Performance - As of the end of 2024, *ST Jiyao's total assets were approximately 1.44 billion CNY, down 24.52% from the previous year, and the net assets attributable to shareholders were negative 776.52 million CNY, a decline of 176.66% [7]. - In the first quarter of 2025, the company reported a revenue of 63.74 million CNY, a year-on-year decrease of 15.53%, and a net loss of 45.17 million CNY, compared to a loss of 40.85 million CNY in the same period last year [8].

在富足板块，集团资产质量稳步提升。中信建投证券以保险业务为例，指出复星葡萄牙保险2024年毛保 费收入达约欧元61.7亿元，充分发挥复星"全球组织+本地运营"能力，通过海外拓展将国际业务占比由 2014年的约5%提高至29.8%；境内两家保险公司迎来关键发展机遇，其中复星保德信人寿的总保费收入 从2023年的人民币43.5亿元大幅增长至2024年的人民币92.5亿元，复星联合健康保险的保费收入也稳步 提升，并且两家公司均实现盈利。两家公司的不断成长有望为集团未来发展奠定坚实基础。 中信建投证券同时看好复星快乐板块业务，指出公司正加速优化品牌布局，推动东方美学概念的打造。 其中，豫园股份积极调整非核心项目，提高财务结构稳定性，同时塑造多品牌战略，包括对黄金珠宝门 店进行升级改造，打造豫园商圈整体品牌形象，塑造多品牌的东方美学概念。复星旅文旗下Club Med 深耕全包高端独家，收入再创新高，三亚亚特兰蒂斯逆势实现入住率新高，维持品牌竞争力。 5月27日，中信建投证券发布了对复星国际（00656.HK）的首次覆盖报告，给予公司"增持"评级。报告 指出，公司下属健康板块拥有包括复星医药、复宏汉霖、复锐医疗等多家上市 ...

Core Viewpoints - The Federal Reserve is expected to actively lower interest rates to a normal range of around 1%, which is significantly lower than the current rate of over 5%. This could lead to capital inflows into emerging markets and A-shares, which are considered to have investment value due to stable dividend yields in sectors like infrastructure and consumer goods, typically around 4%-5% [1] - The company plans to include high dividend yield sectors such as food and beverage and public utilities in its investment portfolio, focusing on assets that are valuable, consistently profitable, and have stable dividend rates [1] - There is an acknowledgment of overproduction in certain commodities in China, but the long-term strategy is to reduce capacity, which is seen as beneficial for the economy. The company believes that the A-share market will remain neutral in the long run despite tariff adjustments [1] Industry Insights - Emerging sectors like AI and robotics are viewed positively, but the company is cautious about investing in specific enterprises due to the current immaturity of these markets. The focus remains on human-driven innovation rather than capital [2] - The aging population in China is projected to increase significantly, with the number of individuals aged 78 and above expected to rise from approximately 32-33 million to around 300 million in 25 years. This demographic shift is seen as a key area for investment, particularly in pharmaceuticals related to chronic diseases [2] - Essential consumer goods, particularly dairy products, are also highlighted as promising investment opportunities despite a declining population, due to the strong competitive position of Chinese companies in this sector [2] Investment Strategy - The company's investment philosophy emphasizes holding onto assets rather than selling, which distinguishes it from other firms. The focus is on selecting resilient asset combinations to manage volatility [3][4] - The company is committed to long-term tracking of enterprises to identify potential champions in the market, particularly in sectors like AI and robotics, which are currently deemed too volatile for investment [4] - Maintaining a positive mindset and avoiding external distractions is crucial for successful investment management, as the company prioritizes its own assessments over market trends [5] Market Outlook - The company believes that the current valuation of A-shares is attractive, suggesting that now is one of the best investment opportunities in decades. While short-term losses may occur, the long-term outlook is optimistic due to stabilizing effects from capacity elimination and supportive government policies [6]

Market Overview - The market experienced narrow fluctuations today, with all three major indices closing lower and trading volume slightly increasing, surpassing 1 trillion yuan but remaining at recent low levels [1][2] - A total of 1,751 stocks rose while 3,480 fell, with 75 stocks hitting the daily limit up and 13 hitting the limit down [2] Sector Performance - Several "car"-related sectors showed strength, driven by three main factors: the overnight surge of Chinese concept stocks Xiaoma Zhixing and WeRide, the expansion of the robotics market from components to applications, and the recent strong performance of unmanned logistics vehicles [1] - New consumption concepts remained hot, with sectors like beauty care and beverages leading the gains, including Kweichow Moutai achieving a six-day four-limit rise [1] - Environmental protection stocks surged, particularly in medical waste treatment and garbage classification, while nuclear power and controllable nuclear fusion sectors also showed strength [1] Fund Flow - Main funds focused on sectors such as general retail, automotive parts, and general equipment, with notable net inflows into stocks like Xue Ren Co., Gongxiao Daji, and Guofang Group [3] Economic Indicators - The National Bureau of Statistics is developing policies to cultivate a national integrated data market, emphasizing the need for collaborative efforts to enhance data market construction [4] - From January to April, state-owned enterprises reported total profits of 13,491.4 billion yuan, a year-on-year decrease of 1.7%, while total operating revenue remained flat at 262,755.0 billion yuan [5] Market Outlook - Huatai Securities maintains a view that the market may experience a period of oscillation, with both upward and downward risks being less visible [6] - Overall market style may rotate between defensive and growth sectors, with a focus on stable or high-dividend industries for defensive strategies and theme growth for growth strategies [8] - Dongfang Securities suggests that the market will primarily undergo oscillation and adjustment, with the Shanghai Composite Index expected to consolidate within the 3,300-3,400 point range [9]

Core Insights - Technology finance is a crucial driver for social progress, economic growth, and national competitiveness, with significant implications for technological innovation and industrial upgrading [1] - Long-term capital plays a vital role in supporting technology enterprises, helping them overcome challenges related to lengthy R&D cycles and high risks [1] - The relationship between public funds and technology innovation enterprises is deepening, with public funds providing comprehensive financial services throughout the lifecycle of technology companies [1] Group 1: Policy and Strategic Focus - The 2025 policy aims to channel more financial resources into technology innovation, encouraging investments that are early-stage, small-scale, long-term, and focused on hard technology [2] - The company is optimizing resource allocation in technology finance, focusing on equity and bond investments to enhance financing channels for technology enterprises [2] - As of the end of 2024, the company has invested in 1,142 technology enterprises across various sectors, with a focus on new-generation information technology, new energy vehicles, and the biopharmaceutical industry [2] Group 2: Product Development and Performance - The company has established dedicated funds for key industries, with a notable focus on the new energy sector, and has launched several industry-specific funds [3] - By the end of 2024, technology investments accounted for approximately 70% of the company's equity assets, with several products performing well in their respective categories [3] - The company has successfully launched a technology-focused ETF that raised 2.982 billion yuan within 45 minutes of its debut, indicating strong market interest [4] Group 3: Research and Development Capabilities - The company is enhancing its investment research capabilities by cultivating talent and optimizing its organizational structure to better understand technology development cycles [5] - A comprehensive research system has been established to analyze technological trends and industry competition, enabling the identification of technology enterprises with long-term growth potential [5] - The company plans to continue improving its research capabilities and innovate its product offerings to capitalize on emerging technology investment opportunities [5]

Group 1 - Recent tariff policy easing, interest rate cuts, and technological advancements are expected to lead the A-share market towards an upward trend after previous risk factors have been released [1] - Despite positive factors, uncertainties remain due to fluctuating Trump policies and weak economic recovery, which may affect market performance until 2025 [2] - The main economic characteristics anticipated for the second half of the year include strong production, recovering investment, stable consumption, and resilient exports [2] Group 2 - The CSI A500 index is designed with an "industry balance" approach, representing a selection of 500 large-cap, liquid securities across various sectors, akin to a domestic "S&P 500" [4] - The index includes approximately 50% traditional value sectors and 50% emerging growth sectors, making it more growth-oriented compared to other value indices [4] - Historical performance shows that the CSI A500 index has achieved a return of 359.17% since its inception, outperforming other major indices like the Shanghai Composite and CSI 300 [5]